Cargando…
Inhibition of Glycogen Synthase Kinase 3 (GSK3) Increases the Cytotoxicity of Enzastaurin
Cutaneous T cell lymphomas (CTCL) represent a spectrum of several distinct non-Hodgkin's lymphomas that are characterized by an invasion of the skin by malignant, clonal lymphocytes. Our lab has previously demonstrated that the Protein Kinase C (PKC) β inhibitor Enzastaurin increases apoptosis...
Autores principales: | Rovedo, Mark, Krett, Nancy L, Rosen, Steven T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116015/ https://www.ncbi.nlm.nih.gov/pubmed/21471986 http://dx.doi.org/10.1038/jid.2011.70 |
Ejemplares similares
-
Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging
por: Pandey, Mukesh K., et al.
Publicado: (2016) -
Regulation of Autophagy by the Glycogen Synthase Kinase-3 (GSK-3) Signaling Pathway
por: Pan, Hsuan-Yeh, et al.
Publicado: (2022) -
Glycogen Synthase Kinase-3 (GSK-3) Regulation of Inhibitory Coreceptor Expression in T-cell Immunity
por: Issa, Mark E., et al.
Publicado: (2021) -
Expression of Glycogen synthase kinase 3-β (GSK3-β) gene in azoospermic men
por: Nazarian, Hamid, et al.
Publicado: (2014) -
In Silico Approaches to Developing Novel Glycogen Synthase Kinase 3β (GSK-3β)
por: Goyal, Shuchi, et al.
Publicado: (2023)